PMID- 12060618
OWN - NLM
STAT- MEDLINE
DCOM- 20021227
LR  - 20091103
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 8
IP  - 6
DP  - 2002 Jun
TI  - Alterations in the frequency of dendritic cell subsets in the peripheral 
      circulation of patients with squamous cell carcinomas of the head and neck.
PG  - 1787-93
AB  - Patients with advanced squamous cell carcinomas of the head and neck (SCCHN) are 
      frequently immunocompromised. Dendritic cells (DCs) are potent antigen-presenting 
      cells that play a role in antitumor immune responses. Using multicolor flow 
      cytometry, the percentages of lineage-negative (LIN(-)) and DR(+) DC precursors, 
      as well as their LIN(-)DR(+)CD11c(+) (myeloid) and LIN(-)DR(+)CD123(+) (lymphoid) 
      subsets, were determined in the peripheral blood of 36 patients with SCCHN before 
      surgery. Peripheral blood mononuclear cells of 28 age- and sex-matched healthy 
      individuals were used as controls. The proportions of LIN(-)DR(+) cells were 
      found to be comparable in the circulation of patients and controls. However, the 
      relative level of DR expression in LIN(-)DR(+) DC was lower in patients than in 
      controls, suggesting a difference in the maturity of DC. The relative proportion 
      of LIN(-)DR(+)CD123(+) cells in the LIN(-)DR(+) subset of DC did not differ 
      significantly in patients compared with normal individuals. However, the 
      percentage of myeloid-derived LIN(-)DR(+)CD11c(+) DCs was significantly lower (P 
      < 0.002) in SCCHN patients than in controls. Of the 13 patients who were 
      restudied 6 weeks after surgery, 9 showed an increase of the myeloid-derived 
      LIN(-)DR(+)CD11c(+) DC subset postoperatively. This observation suggests that 
      deficiency in the myeloid-derived DC precursors in patients with SCCHN is related 
      to the presence of tumor and is reversible. An overall decrease in the 
      myeloid-derived subset of DC could contribute to the failure of SCCHN patients to 
      develop effective antitumor immune responses.
FAU - Hoffmann, Thomas K
AU  - Hoffmann TK
AD  - Department of Pathology, Cancer Institute, University of Pittsburgh School of 
      Medicine, 200 Lothrop Street, Pittsburgh, PA 15213, USA.
FAU - Muller-Berghaus, Jan
AU  - Muller-Berghaus J
FAU - Ferris, Robert L
AU  - Ferris RL
FAU - Johnson, Jonas T
AU  - Johnson JT
FAU - Storkus, Walter J
AU  - Storkus WJ
FAU - Whiteside, Theresa L
AU  - Whiteside TL
LA  - eng
GR  - P01 DE 12321/DE/NIDCR NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antigens, CD)
SB  - IM
EIN - Clin Cancer Res. 2003 Jan;9(1):441.
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/metabolism
MH  - Carcinoma, Squamous Cell/blood/*immunology/pathology
MH  - Case-Control Studies
MH  - Cell Lineage
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - Head and Neck Neoplasms/blood/*immunology/pathology
MH  - Humans
MH  - Lymph Nodes/pathology
MH  - Lymphocytes/immunology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Myeloid Cells/immunology/metabolism
MH  - Neoplasm Staging
MH  - Postoperative Period
MH  - Preoperative Care
EDAT- 2002/06/13 10:00
MHDA- 2002/12/28 04:00
CRDT- 2002/06/13 10:00
PHST- 2002/06/13 10:00 [pubmed]
PHST- 2002/12/28 04:00 [medline]
PHST- 2002/06/13 10:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 2002 Jun;8(6):1787-93.